We recently published an alert in relation to the European Commission’s legislative proposals to replace the current EU regulatory framework for all medicines (including those for rare diseases and for children). One of the...more
Over the last few years, the convergence of life sciences companies and traditional real property developers has led to the emergence of an alternative real estate asset class known increasingly as “propsci.” While this is...more
9/23/2020
/ Asset Management ,
Capital Investments ,
Change of Control ,
Exclusivity ,
Exit Strategies ,
Investors ,
Joint Venture ,
Land Developers ,
Life Sciences ,
Operators ,
Partnership Agreements ,
Public Private Partnerships (P3s) ,
Real Estate Investments ,
Remedies ,
Transfer of Assets